Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead.
Loading...
Embargo End Date
ICR Authors
Authors
Shrestha, S
Morcavallo, A
Gorrini, C
Chesler, L
Morcavallo, A
Gorrini, C
Chesler, L
Document Type
Journal Article
Date
2021-06-14
Date Accepted
2021-05-19
Abstract
The constitutive and dysregulated expression of the transcription factor MYCN has a central role in the pathogenesis of the paediatric brain tumour medulloblastoma, with an increased expression of this oncogene correlating with a worse prognosis. Consequently, the genomic and functional alterations of MYCN represent a major therapeutic target to attenuate tumour growth in medulloblastoma. This review will provide a comprehensive synopsis of the biological role of MYCN and its family components, their interaction with distinct signalling pathways, and the implications of this network in medulloblastoma development. We will then summarise the current toolbox for targeting MYCN and highlight novel therapeutic avenues that have the potential to results in better-tailored clinical treatments.
Citation
Frontiers in oncology, 2021, 11 pp. 694320 - ?
Source Title
Publisher
FRONTIERS MEDIA SA
ISSN
2234-943X
eISSN
2234-943X
Research Team
Paediatric Solid Tumour Biology and Therapeutics
Paediatric Solid Tumour Biology and Therapeutics
Paediatric Solid Tumour Biology and Therapeutics